Zymeworks Inc. Files 8-K: Officer/Director Changes & Compensation
Ticker: ZYME · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001937653
| Field | Detail |
|---|---|
| Company | Zymeworks INC. (ZYME) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2026 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.00001, $520,000, $52,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-departure, director-change, compensation
TL;DR
Zymeworks leadership shakeup and pay details filed today.
AI Summary
On April 1, 2026, Zymeworks Inc. filed an 8-K report detailing the departure of certain officers and directors, as well as compensatory arrangements. The filing also includes financial statements and exhibits related to these changes.
Why It Matters
This filing indicates potential shifts in Zymeworks' leadership and compensation structures, which could impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key personnel and compensation can signal internal shifts or strategic realignments that may carry inherent risks.
Key Numbers
- 0001937653 — CIK Number (Identifies Zymeworks Inc. in SEC filings.)
- 0001193125-26-135610 — Accession Number (Unique identifier for this specific SEC filing.)
- 2026-04-01 — Filing Date (Date Zymeworks Inc. submitted this report.)
Key Players & Entities
- Zymeworks Inc. (company) — Filer of the 8-K report
- 0001937653 (company) — CIK number for Zymeworks Inc.
- 0001193125-26-135610 (dollar_amount) — SEC Accession Number for the filing
- 2026-04-01 (dollar_amount) — Filing date of the 8-K report
- 2026-03-31 (dollar_amount) — Period of report for the 8-K filing
FAQ
What specific officer or director positions were affected by the changes reported in Item 5.02?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' but does not specify names or exact roles within the provided text.
Are the compensatory arrangements mentioned in Item 5.02 related to new hires, departures, or ongoing compensation?
The filing mentions 'Compensatory Arrangements of Certain Officers' in conjunction with departures and appointments, suggesting it could relate to any of these scenarios.
What is the nature of the financial statements and exhibits included in Item 9.01?
Item 9.01 covers 'Financial Statements and Exhibits,' and the listed documents include EX-10.1 and EX-99.1, which are typically exhibits providing further detail on the matters discussed in the 8-K.
What is the significance of the filing date being April 1, 2026, for a report covering the period ending March 31, 2026?
The filing date of April 1, 2026, indicates that Zymeworks Inc. submitted the report on the next business day after the period of report ended, adhering to SEC filing timelines.
What business segment does Zymeworks Inc. operate in, according to the SIC code?
Zymeworks Inc. operates in the 'Pharmaceutical Preparations' sector, as indicated by the SIC code 2834.
Filing Stats: 1,688 words · 7 min read · ~6 pages · Grade level 11.6 · Accepted 2026-04-01 06:16:43
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
- $520,000 — nd benefits: An annual base salary of $520,000, with eligibility to earn an annual dis
- $52,000 — ed by the Company. A signing bonus of $52,000 to be paid on the first scheduled pay d
Filing Documents
- d142598d8k.htm (8-K) — 41KB
- d142598dex101.htm (EX-10.1) — 138KB
- d142598dex991.htm (EX-99.1) — 12KB
- g142598dsp6.jpg (GRAPHIC) — 5KB
- g142598g0401012858720.jpg (GRAPHIC) — 5KB
- 0001193125-26-135610.txt ( ) — 362KB
- zyme-20260331.xsd (EX-101.SCH) — 3KB
- zyme-20260331_lab.xml (EX-101.LAB) — 18KB
- zyme-20260331_pre.xml (EX-101.PRE) — 11KB
- d142598d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: April 1, 2026 ZYMEWORKS INC. (Registrant) By: /s/ Kenneth Galbraith Name: Title: Kenneth Galbraith Chair, President and Chief Executive Officer